| ¤ 100 million plus English speaking people (Largest outside US). |
| ¤ Over 2 million science post graduates. |
| ¤ Large pool of treatment- naïve patients from multiethnic and multiracial
backgrounds. |
| ¤ Easy patient recruitment and compliance. |
| ¤ Favourable Regulatory Policies – Updated Schedule Y. |
| ¤ IPR / WTO, GATT on board. |
| ¤ Cost effective business operations. |
| ¤ International regulatory approvals for GMP/GLP/GCP. |
| ¤ Maximum number of approved GMP plants outside USA. |
| ¤ Excellent quality management, Technology and infrastructure. |
| ¤ Time zone difference facilities 24/7 support. |
| ¤ Presence of all Pharma major & also in-house CROs set up by leading
pharma companies. |
| ¤ Presence of all leading international CROs and several domestic CROs – over
75 CROs. |
| ¤ Strong IT industry availability of IT skilled manpower. |
| ¤ 30 million patients with cardiovascular diseases. |
| ¤ 25 million with Type 2 diabetes. |
| ¤ 10 million with psychiatric disorders |
| ¤ 2 million cases of cancer with 500,000 cases detected every year |
| ¤ 600,000 practicing physicians |
| ¤ 14,000 hospitals. |
| ¤ 700,000 beds. |
| ¤ 17,000 medical graduates per year. |